LATE RECTAL BLEEDING AND GENITOURINARY MORBIDITY AFTER HIGH DOSE RATE BRACHYTHERAPY COMBINED WITH HYPOFRACTIONATED EXTERNAL BEAM RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER

• EBARA Takeshi

  Department of Radiation Oncology, Gunma University Graduate School of Medicine

• AKIMOTO Tetsuo

  Department of Radiation Oncology, Gunma University Graduate School of Medicine Department Radiology, Tokyo Women's Medical University

• KATO Hiroyuki

  Department of Radiation Oncology, Gunma University Graduate School of Medicine

• NODA Shin-ei

  Department of Radiation Oncology, Gunma University Graduate School of Medicine

• TAMAKI Tomoaki

  Department of Radiation Oncology, Gunma University Graduate School of Medicine

• HARADA Kosaku

  Department of Radiation Oncology, Gunma University Graduate School of Medicine

• SHIRAI Katsuyuki

  Department of Radiation Oncology, Gunma University Graduate School of Medicine

• KAWAMURA Hidemasa

  Department of Radiation Oncology, Gunma University Graduate School of Medicine

• SAKURAI Hideyuki

  Department of Radiation Oncology, Gunma University Graduate School of Medicine

• NAKANO Takashi

  Department of Radiation Oncology, Gunma University Graduate School of Medicine

抄録

Purpose: To evaluate late rectal bleeding and genitourinary (GU) morbidity in patients consecutively treated with combined high-dose-rate (HDR) brachytherapy and external beam radiation therapy (EBRT). Materials and Methods: Data from 80 patients treated consecutively from October 2000 to May 2004 were analyzed. The median age was 69 years old, median follow-up 31 months, ranging from 17-59 months. All patients received endocrine therapy before radiation therapy. The patients were divided into low-, intermediate- and high-risk groups (4/24/52 patients) according to the risk factors defined by T-classification, PSA and Gleason score. Fractionation schedules for HDR brachytherapy were prospectively changed, and EBRT was fixed with 3 Gy fractions to 51 Gy. The distribution of fractionation was scheduled as follows; 5 Gy×5 times in 14 patients, 7 Gy×3 times in 19 patients, and 9 Gy×2 times in 47 patients. The rectal bleeding was graded using the toxicity criteria of the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer while the genitourinary morbidities were graded using the toxicity criteria of the Common Terminology Criteria for Adverse Events v.3.0.<br>Results: Grade 2 or worse rectal bleeding developed in 9 patients (11.3%) with the 2-year actuarial probability at 11.2%. Grade 2 and 3 rectal bleeding was recognized in 8 and 1 patients, respectively. Grade 3 morbidity developed in the biopsied sites that were performed in the other hospital. No significant difference was observed in any HDR brachytherapy fractionation schedule. Grade 2 or worse GU morbidities were recognized in 30 patients (37.5%), consisting of 29 Grade 2 patients and 1 Grade 3 patient. Twenty-one patients in Grade 2 morbidity had an increase in the frequency of urination or nocturia, and urethral strictures developed in 3 patients. The 3-year actuarial probability of urethral stricture was 6.0%. One patient experienced Grade 3 incontinent. No Grade 4 GU complications was observed.<br>Conclusion: HDR brachytherapy combined with hypofractionated EBRT for localized prostate cancer is feasible considering severity of late rectal and genitourinary morbidity.

収録刊行物

• 日本放射線腫瘍学会誌

  日本放射線腫瘍学会誌 19 (2), 93-97, 2007

  一般社団法人 日本放射線腫瘍学会

キーワード

• late rectal bleeding and genitourinary morbidity
• HDR brachytherapy
• Hypofractionated EBRT
• localized prostate cancer

詳細情報

• CRID: 1390001204331565440
• NII論文ID: 10021282662
• NII書誌ID: AN10123988
• DOI: 10.11182/jastro.19.93
• ISSN: 18819885
• ISSN: 10409564
• Web Site: https://search.jamas.or.jp/link/ui/2008018093
• 本文言語コード: en
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可